Physician

Jordan Eli Brodsky, M.D.

According to 2025 Medicare claims, Jordan Brodsky, M.D. (NPI: 1386969418) practices rheumatology in the Nassau County-Suffolk County, NY market, with the plurality of this provider's patient population coming from Nassau, NY. This provider's primary affiliated billing organization is RHEUMATOLOGY CONSULTANTS, LLP (NPI: 1851344782; TIN: 113338947) and primary practice location at 11557-2325. Brodsky is affiliated with the CINQCARE ACO REACH LLC (ACO ID: D0284), participating under the REACH model.

Brodsky's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 652 traditional Medicare patients, billed 262,070 HCPCS/CPT codes, and received $2,904,028 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,153 prescription claims across 524 beneficiaries totaling $923,220 in drug costs, led by Xeljanz Xr (Tofacitinib Citrate). 2016 DME data shows 22 claims. Open Payments data shows 204 records totaling $4,069. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $146,018 to $2,904,028. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	134	10,952	$146,018
2016	375	60,352	$820,936
2017	506	109,216	$1,576,092
2018	563	140,094	$1,980,626
2019	603	205,586	$2,435,742
2020	593	260,699	$3,006,440
2021	586	270,545	$3,108,894
2022	618	225,944	$2,462,140
2023	637	260,040	$2,676,177
2024	652	262,070	$2,904,028

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	139	608	$220,443
2016	268	1,291	$236,096
2017	374	2,351	$867,773
2018	461	3,157	$936,344
2019	537	3,526	$1,212,879
2020	516	3,369	$1,333,317
2021	472	3,166	$868,393
2022	507	3,244	$1,049,647
2023	511	3,294	$978,273
2024	524	3,153	$923,220

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	22	$214
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	623	1,811	$110
36415	Insertion of needle into vein for collection of blood sample	620	1,649	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	619	1,647	$8
83615	Lactate dehydrogenase (enzyme) level	618	1,643	$6
85651	Red blood cell sedimentation rate, to detect inflammation, non-automated	620	1,639	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xeljanz Xr	Tofacitinib Citrate	23	690	$129,732
Bosentan	Bosentan	12	360	$113,306
Cosentyx Sensoready (2 Pens)	Secukinumab	13	364	$93,313
Prolia	Denosumab	53	9,480	$91,258
Actemra Actpen	Tocilizumab	23	644	$49,147

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	204	$4,069	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jordan Eli Brodsky, M.D.?

Tedicare shows public-source Medicare data for Jordan Eli Brodsky, M.D. (NPI 1386969418), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jordan Eli Brodsky, M.D. have ACO affiliation data?

Jordan Eli Brodsky, M.D. is shown with ACO affiliation data for CINQCARE ACO REACH LLC (REACH, ACO ID D0284).

What billing organization is linked to Jordan Eli Brodsky, M.D.?

Jordan Eli Brodsky, M.D. is linked to RHEUMATOLOGY CONSULTANTS, LLP (billing NPI 1851344782) in the available physician profile data.

Does Jordan Eli Brodsky, M.D. have Open Payments data?

Jordan Eli Brodsky, M.D. has 204 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.